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Extracellular proteasome-
osteopontin circuit regulates cell 
migration with implications in 
multiple sclerosis
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Benedetta Ferrara1, Loredana Riganti4, Christin Keller7,8, Katharina Janek7, 
Agathe Niewienda7, Chiara Fenoglio9, Melissa Sorosina10, Roberto Cantello11, 
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Daniela Galimberti9, Filippo Martinelli Boneschi10, Cristoforo Comi6,11, Umberto Dianzani6 & 
Michele Mishto7,8,16
Osteopontin is a pleiotropic cytokine that is involved in several diseases including multiple sclerosis. 
Secreted osteopontin is cleaved by few known proteases, modulating its pro-inflammatory activities. 
Here we show by in vitro experiments that secreted osteopontin can be processed by extracellular 
proteasomes, thereby producing fragments with novel chemotactic activity. Furthermore, osteopontin 
reduces the release of proteasomes in the extracellular space. The latter phenomenon seems to occur 
in vivo in multiple sclerosis, where it reflects the remission/relapse alternation. The extracellular 
proteasome-mediated inflammatory pathway may represent a general mechanism to control 
inflammation in inflammatory diseases.
Osteopontin (OPN), a component of bone matrix and a soluble pleiotropic cytokine, plays a pivotal role in several 
diseases such as tumors, myocardial and kidney dysfunctions, and autoimmune diseases. OPN has a particular 
relevance in multiple sclerosis (MS), a disease in which the autoimmune response targets the myelin sheaths 
of the central nervous system (CNS)1. Indeed, in MS secreted OPN stimulates the expression of Th1 and Th17 
cytokines, inhibits apoptosis of autoreactive T cells, and regulates leukocyte adhesion, migration, and trafficking 
into the CNS by binding to CD44 and various integrins2. Increased concentrations of OPN occur in peripheral 
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blood and cerebrospinal fluid during the relapse phase in MS patients3–5. Moreover, OPN is strongly expressed 
in MS lesions. A similar phenomenon occurs also in the experimental autoimmune encephalomyelitis (EAE), an 
MS mouse model in which the administration of the OPN results in rapid induction of relapse, increased level of 
neurological defects and progression of the disease6.
Secreted OPN molecules are cleaved by matrix metalloproteinases and thrombin1. Thrombin cleaves the full 
length OPN (OPN-FL) into N-terminal (OPN-N) and C-terminal (OPN-C) fragments, which exert different 
biological activities1,7,8. Another protease present in different types of biological fluids, including blood, is the 
20S proteasome. Depending on its incorporated catalytic subunit pattern proteasome is named as either stand-
ard proteasome, intermediate-type proteasome or immunoproteasome. Standard proteasome is the most com-
mon proteasome isoform, whereas intermediate-type proteasome and immunoproteasome are expressed during 
inflammation or in immune cells9. The proteasome isoforms possess different proteolytic dynamics10–12. The 
difference in protein turnover results in preferential tasks carried out by either standard proteasome or immu-
noproteasome. For instance, immunoproteasome specifically regulates some aspects of the cytokine-mediated 
inflammation and cell-mediated immunity9. It is generally believed that these immunological tasks are carried 
out by the proteasome only as intracellular protease; indeed, the role of extracellular proteasomes as well as their 
cellular origin and the mechanisms of release remain elusive13. However, it is known that extracellular proteasome 
purified from plasma is proteolytically active14. Active release rather than passive leakage from injured/apoptotic 
cells was suggested to cause the early increase of extracellular proteasome levels in sepsis and severe injury15. 
Active mechanisms of proteasome release have been proposed through various types of extracellular vesicles 
(EVs), i.e. microparticle/ectosomes shedding from the surface of T lymphocytes16, or exosomes derived from 
endocytic compartments of mesenchymal stem cells17. In patients with solid tumors and hematological malignan-
cies, extracellular proteasome levels increase and correlate with occurrence, severity, as well as clinical outcome of 
the diseases18–20. In some autoimmune diseases, such as rheumatoid arthritis, MS and systemic lupus erythemato-
sus, extracellular proteasome levels are increased and are markers of cell damage and immunological activity21,22.
No function of proteasome in the extracellular space has been demonstrated so far.
Results and Discussion
20S proteasome processes OPN molecules and modulates their chemotactic activities. To 
investigate whether extracellular proteasome could be involved in the OPN-mediated inflammatory events, we 
first investigate whether 20S proteasome can fragment OPN molecules in an ubiquitin-independent manner. We 
use purified 20S proteasome because there is no evidence that the entire ubiquitin-proteasome system is present 
and functional in the extracellular space. Furthermore, 20S proteasome is the only active proteasome form that 
has been identified in extracellular microparticles16. Therefore, we perform in vitro degradation of different por-
tions of recombinant OPNs, i.e. OPN-FL (OPN-FL17–314-6His), OPN-N (OPN-FL17-168-6His) and OPN-C (OPN-
FL169-314-6His) by purified erythrocyte 20S standard proteasomes. Testing different ratios of proteasome/OPNs, 
we observe a concentration-dependent degradation of OPN substrates, thereby showing that 20S standard protea-
some can cleave OPNs outside the cell in an ubiquitin-independent manner (Fig. 1a and Supplementary Fig. 1). 
Furthermore, we investigate the degradation rate of the three OPNs by using 20S standard proteasome derived 
from a different cell source, i.e. derived from T2 cells. Thereby we verify that the OPN processing is not a singu-
larity of erythrocyte 20S standard proteasome (Fig. 1b and Supplementary Fig. 1).
Since a key function of OPNs during inflammation is the regulation of cell chemotaxis, we study whether 
proteasome-mediated processing of OPNs affects the in vitro chemotaxis of different cell types, i.e. human umbili-
cal vein endothelial cells (HUVEC), peripheral blood lymphocytes (PBLs) and monocytes (PBMs). These cells are 
recruited through OPN-mediated chemotaxis to the inflammation site in different physiological and pathological 
conditions. HUVECs are a standardized model for investigating the behavior of vascular endothelial cells, which 
are key players in inflammation by regulating inflammatory cell trafficking. Furthermore, the migration of PBLs 
and PBMs in the CNS is considered to be an important pathological inflammatory factor for the MS development.
HUVECs, PBLs and PBMs are treated with OPNs pre-incubated or not with 20S proteasomes. The chemotaxis 
is measured in a Boyden chamber migration assay after 20 h (Fig. 2a). We use as positive control the well-known 
chemotactic factors VEGF-α for the HUVECs and RANTES for PBLs and PBMs.
In HUVECs, the presence of 20S proteasome significantly hampers the chemotactic stimulus by OPN-N 
whereas OPN-FL and OPN-C gain chemotactic activity upon proteasome digestion. Proteasome has only mar-
ginal effects per se on spontaneous migration or in the chemotaxis induced by VEGF-α (Fig. 2a). 20S proteas-
ome also significantly hampers the chemotaxis of PBLs induced by OPN-N, whereas it boosts the chemotaxis 
upon processing of OPN-FL and OPN-C. The proteasome has neither effects per se on chemotaxis nor on the 
RANTES-induced chemotaxis (Fig. 2b). Similar effects of proteasome-catalyzed OPN cleavage are observed in 
PBMs; indeed, proteasome-mediated digestion of OPN-N significantly reduces its chemotactic activity, whereas 
it significantly enhances the PBMs’ chemotaxis induced by OPN-FL and OPN-C. Proteasome has no effect in 
absence of OPNs but it reduces, mildly although significantly, the chemotactic activity of RANTES in PBMs 
(Fig. 2c).
Specific proteasome-generated fragments of the OPN-C stimulate HUVEC and PBL chemo-
taxis. The fact that 20S proteasome can cleave OPN-FL and OPN-C thereby increasing their chemotactic 
activity suggests that 20S proteasome-catalyzed degradation of OPN-FL and OPN-C might unmask cryptic OPN 
chemotactic fragments. Such fragments would then be able to activate chemotaxis better than when they were 
included and folded in the OPN-FL. Similar mechanism has been proposed for the activation of other cryptic 
sites of OPN-FL upon processing by thrombin2,7.
To identify these active fragments, we digest recombinant OPN-C by 20S proteasome and analyze the products 
by mass spectrometry. Among more than hundred identified fragments (data not shown), we select 6 fragments, 
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i.e. OPN-FL217-230, OPN-FL249-266, OPN-FL267-278, OPN-FL268-278, OPN-FL286-306 and OPN-FL292-306 (Fig. 3a), show-
ing dominant mass spectrometry ion peak areas in a 20 h degradation of OPN-C by 20S proteasome from eryth-
rocytes (Supplementary Fig. 2). These peptides are synthetized and analyzed for their ability to induce HUVEC 
chemotaxis. Among them, four peptides – i.e. OPN-FL217-230, OPN-FL249-266, OPN-FL267-278 and OPN-FL292-306 
- exert their chemotactic activity towards HUVECs in a dose-dependent manner (Supplementary Fig. 3). In 
particular, they are effective at the dose of 100 nM (Fig. 3b), which is likely the maximal OPN fragment concen-
tration generated by extracellular 20S proteasome during our chemotaxis experiments (Fig. 2). Their activity is 
sequence-dependent, and not only related to chemical properties of the peptides, since control peptides with 
inverted sequences compared to the functional peptides have no chemotactic activity towards HUVECs (Fig. 3c).
The same response towards the 6 OPN-derived peptides is observed for the cell migration of PBLs. Indeed, the 
four peptides OPN-FL217-230, OPN-FL249-266, OPN-FL267-278 and OPN-FL292-306 are chemoattractant also towards 
PBLs, whereas the peptides OPN-FL268-278, OPN-FL286-306 exert no effect (Fig. 3d).
According to the prediction of the OPN-FL 3D structure (Fig. 3e) the four active OPN fragments are either 
buried in the OPN-FL structure, or part of loops and strongly secondary structured alpha-helices.
OPNs reduce the release of proteasome by endothelial cells in the extracellular space. In bio-
logical systems, negative feedback loops exist to control the activity of mediators. Thus, we investigate whether 
a reciprocal regulation could exist between OPN and extracellular proteasome, whereby OPNs regulate protea-
some release in the extracellular space. To this end, we measure the concentration of extracellular proteasome 
in cultures of HUVECs, PBLs or PBMs upon treatment with the three OPNs, and either VEGF-α or RANTES, 
respectively. We observe a significant decrease in the extracellular proteasome concentration in the medium of 
HUVEC cultures upon stimulation with either each of the three OPNs or with VEGF-α compared to untreated 
cells (Fig. 4). On the contrary, these cytokines do not have any effect on proteasome released by PBLs (Fig. 4); a 
similar lack of effect is also detected with PBMs (data not shown).
Figure 1. Extracellular 20S standard proteasomes cleave OPN molecules. (a) Representative in vitro 
digestion (n = 3) of recombinant OPN-FL, OPN-N, OPN-C by different amount of human erythrocyte 
20S standard proteasome. (b) Degradation kinetics of OPN-FL, OPN-N and OPN-C by T2 20S standard 
proteasomes are shown by representative Western Blot assay (left panel; the proteasome α 4 subunit is used as 
control marker since it is incorporated in each proteasome). The density of the Western Blot bands is measured 
and the corresponding relative OPNs’ degradation computed (right panel; mean and SD of 4–5 independent 
experiments measured in duplicate). The relevant bands of the Western Blot assays shown here are cropped 
from the full blots shown in Supplementary Fig. 1. No significant differences between the degradation rate of the 
three OPNs are observed by Kruskal-Wallis test. In (b) we use a ratio OPNs/proteasome that roughly resembles 
that observed in the peripheral blood of healthy and MS donors (Fig. 5) and that used in the cell migration 
experiments (Fig. 2).
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Figure 2. Extracellular proteasome modulates chemotactic activity of OPN molecules. (a) Representative 
pictures of migrated HUVECs (stained by crystal violet) treated with OPNs ± 20S proteasome are displayed. 
The quantitative effect of OPNs ± 20S proteasome (and VEGF-α as positive control) on the HUVEC chemotaxis 
(n = 6–38) is shown. (b) Representative pictures of migrated PBLs treated with OPNs ± 20S proteasome 
are displayed. The quantitative effect of OPNs ± 20S proteasome (and RANTES as positive control) on the 
chemotaxis of PBLs (n = 6–18) is shown. (c) Representative pictures of migrated PBMs treated with OPNs ± 20S 
proteasome are displayed. The quantitative effect of OPNs ± 20S proteasome (and RANTES as positive control) 
on the chemotaxis of PBMs (n = 11–13) is shown. In (a–c) cell migration is measured by applying the Boyden 
chamber migration assay; values are percentage of treated vs untreated cells that migrated after 20 h and are the 
mean and the SD of independent experiments. Wilcoxon test for paired samples p < 0.05 are shown.
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An inverse correlation between extracellular OPN and proteasome is confirmed in peripheral 
blood of RRMS patients. We then verify whether this negative feedback loop between extracellular OPN 
and proteasome concentration is detectable also in vivo. This could be detected through an inverse correlation 
of extracellular OPN and proteasome concentration. We would expect that the proteasome release is regulated 
by different factors in non-inflamed and inflamed subjects. In the latter, when OPN function and concentra-
tion raises, the impact of OPNs in the release of proteasome might become evident and an inverse correlation 
between OPN and proteasome concentration should be detectable in bodily fluids. This should be the case in the 
relapsing-remitting multiple sclerosis (RRMS), which is the most prevalent form of MS, and it is anticipated in 
85% of people by an acute onset named clinically isolated syndrome (CIS). RRMS is characterized by disability 
episodes (relapses) followed by a complete or partial recovery (remission). During (or right before) the relapse 
Figure 3. Location and chemotactic effect of proteasome-generated OPN fragments towards HUVECs and 
PBLs. (a) The sequence of the OPN-FL (P10451.1) and of the studied proteasome-generated OPN fragments is 
here disclosed. (b) The effect of different OPN fragments (100 nM) on the HUVEC chemotaxis is shown. 
(c) The comparison between the efficacy of the proteasome-generated OPN fragments and of the corresponding 
peptides with inverted sequence in inducing chemotaxis in HUVECs is shown. (d) The effect of the studied 
OPN fragments (50 nM) on the PBL chemotaxis is shown. (b–d) Values are reported as percentage of treated 
vs untreated cells that have migrated after 20 h and are expressed as the mean and the SD of independent 
experiments (n = 4–14). Cell migration is measured by the Boyden chamber migration assay. Wilcoxon test 
for paired samples p < 0.05 are shown. (e) Tertiary structure prediction of OPN-FL. The predicted structure is 
shown as a cartoon representation indicating disordered regions and α -helices. Highlighted are the sequences 
produced by proteasome that show strong chemotactic activity and the thrombin cleavage site; colors 
correspond to (a). The structure is predicted with I-TASSER server.
www.nature.com/scientificreports/
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of RRMS patients, the levels of OPN rise together with the exacerbation of the CNS inflammation, while they 
decrease in the following remission1.
In line with our hypothesis, in the sera of a first Italian cohort (Supplementary table 1), we observe a signif-
icantly higher concentration of OPNs in RRMS patients in relapse compared to those in remission and healthy 
donors (Fig. 5a), and a significant inverse non-linear correlation between extracellular proteasome and OPN 
concentrations by pooling together relapses and remissions (Fig. 5b). To further assess the robustness of this cor-
relation, we perform a bootstrap analysis to obtain confidence intervals. All bootstrap samples show a significant 
correlation coefficient between 0.25 and 0.55, which assures that the observed correlation is stable to potential 
outliers (Fig. 5b). This inverse correlation within the RRMS cohort suggests that the dramatic increase of OPN 
levels in the relapse leads to a corresponding decrease of serum proteasome concentration. According to our 
hypothesis, such effect should disappear during the remission when the secreted OPN concentration drops. This 
is indeed what we observe in the serum of the RRMS cohort: the extracellular proteasome levels are significantly 
higher in Italian RRMS patients in remission compared to those in relapse (Fig. 5c). They are also higher than 
those measured in healthy controls in agreement with the study of Minagar and colleagues22. This latter observa-
tion is confirmed in a second German cohort of RRMS patients in remission compared to healthy donors as well 
as of CIS patients compared to healthy donors (Fig. 5d).
EVs-free extracellular proteasome varies amongst disease groups. Extracellular vesicles (EVs) 
have been hypothesized to be one of the mechanisms for the proteasome release in the extracellular space. EVs 
have been also suggested as the active delivery mechanism of biological mediators in peripheral blood and other 
bodily fluids of several diseases including MS16,23,24. Hence, we investigate whether serum EVs might be respon-
sible for the differences in extracellular proteasome concentration we observed in RRMS and CIS cohorts com-
pared to healthy donor cohort.
Different factors might affect EV stability in extracellular fluids and lead to difference when plasma and serum 
are considered25. Therefore, we initially analyze the proteasome content in large vesicles (p2p3, > 100 nm), small 
vesicle/exosomes (p4 < 100 nm) or all vesicles (p2p4), as well as the corresponding supernatants centrifuged from 
freshly isolated healthy donor plasma and serum by western blotting. Proteasomes are present in both large 
and small vesicle fractions and at a similar extent comparing plasma and serum samples (Fig. 6a). By ELISA on 
healthy donor plasma and serum supernatants, we find that a large portion of extracellular proteasomes is not 
associated with EVs, both in frozen and fresh samples (Fig. 6b). Accordingly, extracellular proteasomes are mainly 
present in the EVs-depleted serum in a sub-cohort of both German healthy donors (n = 11; mean = 74.4 ± 14.8%) 
and German CIS patients (n = 14; mean = 74.9 ± 12.0%). In the same sub-cohorts, the amount of extracellular 
proteasomes measured in non-fractionated serum correlates with that of the supernatant after p2p4 separation 
(Fig. 6c) but not with vesicular proteasomes (p2p4 fraction) (Fig. 6d), thereby suggesting that the variation of 
extracellular proteasome we detect in the CIS and RRMS patient sera is not due to the EVs’ content.
Figure 4. OPNs and VEGF-α partially inhibit the release of proteasome by HUVECs. The proteasome 
release by HUVECs (left panel) and PBLs (right panel) in serum-free medium with OPN-FL, OPN-N, 
OPN-C and VEGF-α (with HUVECs) or RANTES (with PBLs) is shown. Values are reported as proteasome 
concentration ratio of treated vs untreated cells and they correspond to the mean and the SD of independent 
experiments (HUVECs, n = 14; PBLs, n = 10) measured by ELISA. Statistically significant variations from the 
control are detected by Wilcoxon test for paired samples and p < 0.05 are annotated.
www.nature.com/scientificreports/
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Conclusions
Extracellular proteasome has been proposed as a suitable biomarker in some cancers and autoimmune diseases, 
potentially allowing for better diagnosis, patient stratification, and prediction of the response to therapy18–21, even 
though its function is not yet understood. Here, we elucidate one of its potential functions in the extracellular space. 
The OPN chemotactic activity toward three cell types is indeed enhanced by extracellular proteasome through the 
release of active OPN fragments during OPN processing. These peptide fragments are buried in the C-terminal 
portion of OPN-FL. When they are removed from the original protein they have likely lost their secondary con-
formation and the absence of surrounding bulky structures might facilitate an enhanced binding to chemotac-
tic receptors. This could enhance their chemotactic activity towards migrating cells, such as HUVECs, PBLs and 
PBMs. Similar mechanism has been proposed for the activation of other cryptic sites of OPN-FL upon processing 
by thrombin2,7. The action of these novel OPN peptides seems to be sequence-specific since peptides with inverted 
sequences do not have chemotactic activity and small variations of the sequence alter the peptide efficacy. Indeed, 
the removal of a single residue from the peptide OPN267-278 remarkably reduces its chemotactic activity, whereas the 
removal of six residues from the peptide OPN286-306 confers a stronger chemotactic efficacy to the peptide (Fig. 3 
and Supplementary Fig. 3). It is noteworthy that peptide hydrolysis might not be the only mechanism whereby 
extracellular proteasome modulates OPN activities. Indeed, proteasome is also able to ligate peptide fragments 
thereby generating novel peptides with sequences that are not present in the parental protein. This process, named 
proteasome-catalyzed peptide splicing, is much more frequent than expected26–28 and it has been already hypothe-
sized to be involved in generating autoimmune epitopes in diseases such as MS29,30. Although proteasome-generated 
spliced peptides have been investigated so far only as target of T cell response, they might have other functions and 
cells might use them to multiply the variety of functional peptides derivable from a parental protein.
Figure 5. Serum OPN and proteasome levels inversely correlate in RRMS patients. (a) Serum OPN 
concentration is significantly increased in an Italian cohort of RRMS patients in remission (RRMS Rem, n = 48) 
and relapse (RRMS Rel, n = 24) compared to healthy controls (HC; n = 28), as well as in RRMS Rel vs RRMS 
Rem. The Kruskal-Wallis test is applied with a Bonferroni correction for multiple comparisons, and p < 0.05 
are reported. (b) Serum OPN and proteasome concentration in Italian RRMS patient cohort (n = 72) are 
nonlinearly and inversely correlated as shown by plotting OPN vs 1/extracellular proteasome concentrations 
(Pearson’s test, p < 0.001; C value is shown in the chart). Bootstrap test using 1000 samples with 100% of the 
data shows a significant correlation coefficient between 0.25 and 0.55 (right panel). (c) Serum proteasome 
concentration in Italian healthy donors (n = 62), RRMS patients in remission (RRMS Rem, n = 50) or in relapse 
(RRMS Rel, n = 25). (d) Serum proteasome concentration in German healthy controls (n = 50), RRMS patients 
in remission (RRMS Rem, n = 12) and CIS patients (n = 35). 3–6 technical ELISA replicates for each samples 
are used in the analysis. Kruskal-Wallis test is applied for multiple comparison with Bonferroni correction and 
p < 0.05 are reported. In (a,c,d) the median, the 25–75 quartiles (the grey box), the 0–100 quartiles (the error 
bars) and the outliers are shown.
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The cellular origins of the serum proteasome remain unknown, and we can only refer to the extensive study 
of Zoeger et al.14, who have shown how proteasome subtype profiles cannot be assigned to any of the investigated 
blood cells. Here, we demonstrate that although EVs contain proteasomes, only a minor portion of extracellular 
proteasome that we measure in sera is stored by EVs. This portion does correlate neither with total extracellular 
proteasome concentration nor with the variations we observe in CIS sera. We cannot exclude the possibility that 
extracellular proteasome is initially released in short-lived EVs, whose content is rapidly liberated into the extra-
cellular space after the release from the cells. Indeed, the content of these short-lived EVs would be detected as 
free extracellular proteasome in our assays. However, multiple mechanisms of release are a common feature for 
both secretory molecules (ATP), or proteins lacking a conventional leader sequence (IL1-β or tau protein); these 
could be used also by proteasome.
It is noteworthy that, in this study, we investigate only the chemotactic effect of OPNs; however, OPNs also 
mediate other pro-inflammatory mechanisms involved in MS. Indeed, in EAE it has been demonstrated that 
OPN is able to trigger the neurological relapse by supporting the recruitment of autoimmune T cells into the 
CNS, by stimulating the expression of Th1 and Th17 cytokines, and by inhibiting T cell apoptosis through the 
regulation of Foxo3 and NF-kB transcription factors expression6. Additionally, activated T cells can secrete OPN, 
thus enhancing the Th1 and inhibiting the Th2 responses2. Recently, it has been demonstrated that the immuno-
proteasome is also involved in the regulation of Th1 and Th17 cytokine production and T cell differentiation9,31,32. 
Moreover, the administration of a selective immunoproteasome inhibitor prevents EAE progression and ame-
liorates a relapse when the treatment is started in the recovery phase. These effects depend on the reduction of 
immune cell infiltration into the brain and spinal cord, as well as the inhibition of Th17 cell differentiation33. Thus, 
based on our in vitro results, we might speculate that the role of immunoproteasome in promoting EAE could be, 
at least in part, the direct outcome of an altered activation of OPN pro-inflammatory mechanisms by extracellular 
immunoproteasome.
Figure 6. The main portion of serum extracellular proteasome is not stored in isolated EVs. (a) Representative 
Western blot analysis (n = 3) of p2p3 (large vesicles), p4 (small vesicles) and p2p4 (all vesicles) protein 
extracts are shown. They derive from healthy donor’s freshly-isolated plasma and serum samples. Cell lysate 
from lymphoblastoid cell lines is used as control. (b) The quantitative evaluation of extracellular proteasome 
concentration is here shown and is obtained by applying ELISA on the fresh plasma (n = 5) and serum (n = 3) or 
frozen serum (n = 3) of healthy donors, or on their corresponding EV-free supernatants, which are obtained by 
removing the p2p4 vesicles upon ultra-centrifugations. (c) The correlation between the proteasome concentration 
in the total serum and the EV-free (p2p4-free) serum supernatant of a subset of German healthy donor (n = 11) 
and CIS patient (n = 14) cohorts (measured by ELISA) is shown. A statistically significant positive correlation 
is observed between the extracellular proteasome concentration in the EV-free (p2p4-free) serum supernatant 
and in the unfractioned serum (Pearson’s test; in healthy donors, p = 0.001; in CIS patients, p < 0.001). (d) The 
proteasome concentration in p2p4 vesicles of a subset of healthy donors (n = 10) and CIS patients (n = 11) is 
shown. It is measured by Western blotting and by using anti-α 6 proteasome subunit antibody. It is expressed as 
proteasome concentration relative to that of the cell lysate of lymphoblastoid cell lines. No correlation between the 
extracellular proteasome concentration measured in serum p2p4 vesicles or in whole serum is observed. Pearson ’s 
test C values are reported in each chart.
www.nature.com/scientificreports/
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Materials and Methods
In vitro processing of cytokines by purified 20S proteasome. 20S proteasomes are purified from 
human erythrocytes or T2 cell line, which contain only standard proteasome. The purity of 20S proteasome 
preparation has been previously shown12.
For the in vitro degradation assays, 0.4 μ g recombinant OPN-FL (OPN17-314-6His), OPN-N (OPN17-168-6His) 
and OPN-C (OPN169-314-6His) are incubated in 20 μ l solution at 37 °C with different concentration of erythrocyte 
20S proteasome for 4 h (Fig. 1a), or 4 μ g erythrocyte 20S proteasome for 20 h at 37 °C (Supplementary Fig. 2), 
or by 3.5 μ g 20S proteasomes from the T2 cell line for 1–4 h (Fig. 1b). The ratio of OPNs/proteasomes used 
in the kinetics assays mimics that observed in serum of healthy controls and MS patients (Fig. 5), and that 
used in the cell migration assays (Fig. 2). Substrate degradation is detected by immunoblotting using antibod-
ies for human OPN-N, or -C (1: 250 Maine Biotechnology Services), or OPN-FL (1: 400 Enzo Life science) 
as previously described34. A secondary anti-mouse or anti-rabbit horseradish peroxidase-conjugated antibody 
(1:5000; Calbiochem) is used for 1.5 h at room temperature followed by ECL detection (Amersham). The samples 
described in Supplementary Fig. 2 are analyzed by mass spectrometry (see below).
OPN fragment identification and peptide synthesis. Liquid chromatography tandem mass spectrom-
etry analyses are performed as previously described35 on a 4700 proteomics Analyzer (ABSCIEX, Framingham, 
MS) off-line coupled with a Dionex UltiMate 3000 RSLC system and Probot fractionation device (Thermo 
Scientific, Idstein, Germany). Mass spectrometry spectra are recorded in the range of m/z 600–4000 and with the 
accumulation of 1200 sub-spectra. Fragmentation spectra are measured from the five most intensive precursor 
ions (S/N > 40). 5000–10.000 laser shots are accumulated. The peak lists are generated by the “Peak to Mascot” 
tool of the 4000er Series Explorer v3.6. For data analysis the MASCOT server (version 2.3, Matrixscience, 
London, UK) is used. Database searches are performed using SwissProt (2014_08; 546238 protein sequences) and 
the following parameters: no enzyme, mass tolerances for precursor ions 100 ppm and for fragment ions 0.5 Da. 
Peptides of OPN-C produced by 20S proteasome in vitro are accepted as identified if they provide a MASCOT 
score for identity with p < 0.01. MALDI/TOF/TOF fragmentation spectrum of OPN-FL217-230 does not fulfill 
this criterion. However, its identity is verified by comparison with the fragment pattern of the synthetic analog. 
The reference peptide is synthesized in-house using Fmoc solid phase chemistry as previously described35, and 
have the following sequences: WDSRGKDSYETSQL (OPN217-230), KANDESNEHSDVIDSQEL (OPN249-266), 
SKVSREFHSHEF (OPN267-278), KVSREFHSHEF (OPN268-278), VVDPKSKEEDKHLKFRISHEL (OPN286-306), 
and KEEDKHLKFRISHEL (OPN292-306). Inverted peptides are designed by inverting the sequence of the 
related peptides identified in the proteasome-mediated digestion of the OPN-C have the following sequences: 
LQSTEYSDKGRSDW (invertedOPN217-230), LEQSDIVDSHENSEDNAK (invertedOPN249-266), FEHSHFERSVKS 
(invertedOPN267-278), and LEHSIRFKLHKDEEK (invertedOPN292-306).
Spatial localization of OPN fragments within OPN-FL 3D structure. I-Tasser36 is used to predict the 
tertiary protein structure of OPN-FL. The c-score (value between -5 and 2, where higher c-scores indicate higher 
confidence in the predicted structure) of the best model predicted by I-TASSER is − 3.33, which is comparable 
to the confidence obtained by predicting the structure of OPN-C37. Pymol is used for graphic visualization (The 
PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC).
Cell culture. HUVECs are isolated from human umbilical veins via trypsin treatment (1%) and cultured in 
M199 medium (Sigma-Aldrich) with the addition of 20% FCS (Invitrogen, Burlington, ON, Canada) and 100 U/ml 
penicillin, 100 mg/ml streptomycin (Invitrogen), 5 UI/ml heparin (Sigma-Aldrich), 12 mg/ml bovine brain 
extract, and 200 mM glutamine (Hyclone Laboratories). HUVECs are grown to confluence in flasks and used at 
the second to fifth passage. The use of HUVECs is approved by the Ethics Committee of the “Presidio Ospedaliero 
Martini” of Torino and conducted in accordance with the Declaration of Helsinki. Written informed consent is 
obtained from all donors. 2*103 HUVEC are used for migration assay and cultured in M200 medium (GIBCO) 
with 100 U/ml penicillin, 100 mg/ml streptomycin and 200 mM glutamine.
Peripheral blood mononuclear cells are separated from buffy coat, provided by the local Blood Transfusion 
Service of Novara, Italy, with the Ficoll-Hypaque reagent (Limpholyte-H, Cedarlane Laboratories) by 
density-gradient centrifugation. PBLs are obtained from peripheral blood mononuclear cells cultured in RPMI 
1640 (Euroclone) supplemented with 10% FBS, L-glutamine, penicillin-streptomycin, and let 2 h on plate 
to remove the adherent monocytes; PBMs (CD14+) are isolated with the EasySepTM Human CD14 Negative 
Selection Kit (StemCells Techologies, Vancouver, BC, USA). For both cell types the cell purity is checked by 
immunophenotypic analysis and is higher than 98%. 5*104 PBLs or 2*104 PBMs are used for migration assay and 
cultured in medium X-vivo 20 or X-vivo 15 (Lonza), respectively, with 100 U/ml penicillin, 100 mg/ml strepto-
mycin and 200 mM glutamine.
Cell migration assay. In the Boyden chamber (BD Biosciences) migration assay, cells are plated onto the 
apical side of 50 μ g/ml Matrigel-coated filters (0.5 μ m pore size, Neuro Probe, BIOMAP snc) in M200 serum-free 
medium for HUVECs or X-vivo serum-free medium for PBLs or PBMs.
10 μ g/ml OPN-FL, OPN-C and OPN-N (Fig. 2) or 10–500 nM OPN-C peptides (Fig. 3 and Supplementary Fig. 3), 
are placed in the basolateral chamber; 10 ng/ml vascular endothelial growth factor-α (VEGF-α ; Sigma-Aldrich) 
or 1 ng/ml recombinant human RANTES (rh RANTES/CCL5; ImmunoTools GmbH) are placed as reference 
chemoattractant for the HUVECs or the PBLs and the PBMs, respectively.
20S proteasome is pre-incubated with OPN-FL, OPN-C and OPN-N (with ratio ng proteasome: ng 
OPNs = 20:1) for 2 h at 37 °C under 5% CO2 and subsequently placed in the basolateral chamber.
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The chamber is incubated at 37 °C (5% CO2). After 20 h, the cells on the apical side are wiped off with Q-tips. 
The cells on the bottom of the filter are stained with crystal violet (HUVECs), or eosin Y and thiazine (PBLs and 
PBMs), and all counted with an inverted microscope (magnification x40). Data are shown as percentage of the 
treated cells migration vs the control migration measured for untreated cells. Control migration of the exper-
iments shown in Fig. 2 is (mean ± SEM) 287 ± 39 cells for HUVECs (n = 38), 175 ± 28 for PBLs (n = 18), and 
250 ± 32 for PBLs (n = 13).
Proteasome release in cell cultures. 7*104 HUVECs are seeded in 48 well plates with M199 20% FCS 
medium. After 20 h HUVECs are twice washed with M200 medium and refilled with M200 medium. Then, 
HUVECs are treated with 10 μ g/ml OPN-FL, OPN-C, OPN-N or 10 ng/ml VEGF-α . After 6 h culture the super-
natant is collected. Four replicate wells are used for each donor (n = 14).
1 × 105 lymphocytes are seeded in 96 well plates with RPMI 1640 medium + supplements. After 20 h lympho-
cytes are washed and refilled with X-Vivo 20 medium. Then, lymphocytes are treated with 10 μ g/ml OPN-FL, 
OPN-C, OPN-N or 1 ng/ml RANTES. After 20 h culture the supernatant is collected. Four replicate wells are used 
for each donor (n = 10).
Medium supernatant is processed by ELISA assay to measure the proteasome concentration (see below).
Trypan blu assay is assessed in order to evaluate cell viability. Viable cells are measured, by 
2,3-bis(2-methoxy-4-nitro-5sulphophenyl)-2H- tetrazolium-5-carboxanilide (Sigma-Aldrich) inner salt reagent, 
at UV 570 nm, as described by the manufacturer’s protocol.
Donor enrolment, blood drawing, serum separation. The blood samples of the Italian cohorts are 
obtained after informed consent and ethical approval by the University of Piemonte Orientale “Amedeo Avogadro” 
(Novara; ethical committee approval: CE 18/04), IRCCS Fondazione Ospedale Maggiore Policlinico and Ospedale 
San Raffaele (Milano; ethical committee approval: Banca-INSPE and MSGENE02). The blood samples of the 
German cohort are obtained after informed consent and ethical approval by the Clinical and Experimental MS 
Research Centre, Charité – Universitätsmedizin Berlin (Berlin; ethical committee approval: EA1/182/10). All 
methods and procedures are performed in accordance with the relevant guidelines and regulations of the ethical 
committee approvals. RRMS and CIS patients as well as age-, gender-, and ethnicity-matched healthy controls 
without a history of any neurological or other chronic disease are recruited (Supplementary Table 1). All par-
ticipants are older than 18 years; an information sheet related to the study is provided and an informed consent 
is undersigned by each participant. Diagnosis of MS is made according to the McDonald 2010 criteria38. The 
clinical workup and examinations of MS patients at the visit include: detailed medical and demographic history, 
neurological examination, determination of the expanded disability status scale score, brain Magnetic Resonance 
Imaging, type of therapy (Glatiramer acetate or IFN-1β ). Inclusion criteria are the following: age > 18 years, a 
first clinical event suggestive of central nervous system demyelination within 6 months before inclusion into the 
study for CIS patients or a diagnosis of RRMS according to the McDonald 2010 criteria38 within 24 months before 
inclusion into the study. Exclusion criteria are the inability or unwillingness to provide informed consent, a his-
tory of alcohol or drug abuse, any ocular diseases precluding performance of optical coherence tomography, and 
any conditions (e.g. allergies) or devices (e.g. cardiac pacemaker) precluding MRI examinations. Serum samples 
of RRMS patients are obtained from 10 ml of peripheral blood, which are drawn either at the time of relapse (2–7 
days from its onset) or in remission (after 1–12 months from the last relapse) as previously reported39. The RRMS 
patients receive a corticosteroid treatment after the blood withdrawal during the relapse.
Extracellular proteasome and OPN quantification in serum. The concentration of the extracellular 
proteasomes is measured in serum by enzyme-linked immunoabsorbent assay (ELISA), as previously described 
with minor modifications40. Plates (FA9439454, Nunc Immuno MaxiSorp Surfaces, Thermo Fisher Scientific 
Inc.) are coated overnight with mouse monoclonal antibodies towards 20S proteasome subunit α 6 (PW 8100, 
Enzo Life Sciences Inc.) 1:1500 in 100 μ L PBS at pH 7.4. The plates are washed 5 times in PBS-Tween20 (PBST) 
0.1% and incubated 6 h at room temperature with a blocking solution of PBST-BSA 1% to prevent non-specific 
bindings of the samples. Samples are diluted in PBST-BSA 1% (serum 1:15–1:30; plasma/serum supernatant 1:15; 
medium of in vitro experiments 1:2.5–1:10) and 100 μ l are applied to each well overnight at 4 °C. Standard curves 
are established for every plate using purified 20S proteasomes with concentrations ranging from 0 to 100 ng/ml 
(8 linear dilution steps). The plates are washed 3 times and 100 μ l of anti-proteasome rabbit polyclonal antibody 
1:750 (K42, in house) in PBST solution are added for 3 h at 4 °C. After additional washing steps, 100 μ l of 1:15000 
peroxidase-conjugated mouse anti-rabbit IgG (11-035-003, Jackson ImmunoResearch Laboratories Inc.) in PBST 
solution are used for antigen detection (1 h at 4 °C). Finally, plates are washed five times and 100 μ l of TMB sub-
strate added (T0440, Sigma-Aldrich). The reaction is stopped with sulphuric acid and OD-values are determined 
at 450 nm. Serum from a young healthy control is added in each plate as internal control.
Serum OPN concentration is evaluated by ELISA according to the protocol provided by the manufacturer 
(Calbiochem) as previously described39. The optical density is measured with a microplate reader (Bio-Rad).
All assays are performed in duplicate in three independent measurements, and the observer is blinded to the 
diagnosis.
Analysis of EVs. 100–200 μ l of human serum and plasma are diluted 1:5 in PBS and processed by serial 
centrifugations to collect EVs41 into p2p3, p4 or p2p4 fractions. The supernatants are recovered and analyzed 
for extracellular proteasome content by ELISA, as above described, thereby reckoning the proportion of extra-
cellular proteasomes in the supernatant vs unfractionated sample. The pellets are lysed in 20 μ l of RIPA buffer 
supplemented with Protease Inhibitor Cocktail (P2714, Sigma Aldrich) and the protein content is analyzed by 
SDS-PAGE and western blotting, as previously described42. Anti-α 6 proteasome subunit antibody (PW 8100, 
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Enzo Life Sciences Inc.) is used to measure total proteasomes content within isolated EVs. Crude protein extract 
from lymphoblastoid cell line is used as control and for normalizing data of samples loaded in different gels. Equal 
loading of EVs proteins is assessed by SDS-PAGE and Coomassie Blue gel staining.
Statistical analysis. For the statistical analysis, peripheral blood samples are analyzed separately in the fol-
lowing categories: RRMS in relapse, RRMS in remission and healthy controls for Italian samples, and CIS, RRMS 
in remission and healthy control cohorts for German samples. For each sample, serum levels of extracellular 
proteasome and OPN contents are measured in triplicate and the mean value is calculated. Each cohort is tested 
to assess whether extracellular proteasome correlated to gender or age of the donors, as well as to the clinical 
history and parameters measured at the withdrawal (data not shown). Data are tested for normality distribution 
and homoscedasticity by Shapiro-Francia, Shapiro-Wilk and Skewness-Kurtosis tests. To identify significant dif-
ference between groups, One-way ANOVA, Mann-Whitney or Kruskal-Wallis tests are applied depending on 
the underlying distributions. To identify significant variation in proteasome release or chemotaxis in cell culture 
upon different stimuli we apply Wilcoxon test for paired samples. Pearson’s correlation coefficients are computed 
for correlation analyses. Descriptive statistics are carried out with STATA v.9.0 (Stata Corp.), SPSS (version 17) 
and R; a p-value < 0.05 is considered statistically significant. After applying Bonferroni correction method for 
multiple comparisons, the p value threshold for significance is set at p = 0.0083. A bootstrap test (1000 samples 
using 100% of the data) is performed to obtain confidence intervals for the correlation coefficient between OPN 
and 1/extracellular proteasome. We extract the bootstrap distribution of the correlation coefficient as well as the 
5% and 95% quantiles for the confidence intervals.
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